SynthesisFrontiers in medicine2025
Biomaterial-driven regenerative drug delivery: a vicennial bibliometric landscape.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Biomaterials are increasingly central to innovations in drug delivery and regenerative medicine, driving new therapeutic strategies for chronic diseases and tissue repair. Despite rapid growth, a comprehensive, data-driven overview of this evolving interdisciplinary landscape has been lacking. Methods: Here, we present a bibliometric analysis of articles and reviews published in the Science Citation Index Expanded (Web of Science Core Collection) from January 2005 to December 2024. Results and discussion: The findings present a bibliometric visualization that highlights key trends in publication volume, geographical distribution of research, leading institutions, top journals, research categories, and emerging keywords. Cross-disciplinary integration of biomaterials, regenerative medicine, and drug delivery is accelerating advances in stem cell-based therapies, tissue engineering, and precision drug delivery platforms. Promising frontiers include personalized medicine, organoids, organ-on-chip technologies, and digital modelling of cellular systems. However, significant challenges remain in scalability, safety, and regulatory translation. This work provides a comprehensive reference for navigating current trends and identifying future opportunities in biomaterial-driven regenerative drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.